Category: Biotherapeutic Index

  • Citric Acid Cycle

    Injection Solutions

    Composition: 1 combination pack (10 ampoules of 1.1 ml) contains 1 ampoule each of:

    • Magnesium-manganum-phosphoricum-Injeel
    • Natrium pyruvicum-Injeel
    • Natrium oxalaceticum-Injeel
    • Acidum citricum-Injeel
    • Acidum cis-aconiticum-Injeel
    • Baryum oxalsuccinicum-Injeel
    • Acidum alpha-ketoglutaricum-Injeel
    • Acidum succinicum-Injeel
    • Acidum fumaricum-Injeel
    • Acidum DL-malcium-Injeel

    All diseases classified as cellular phases (degeneration phases, dedifferentiation phases) and which are consequently characterized by defective enzymatic control, blockages, and/or defective cellular oxidation, eg:

    • Paresis, neuralgia, toxic neuritis, vegetative dystonia, migraine.
    • Dermatosis, neurodermitis, pruritus (including pruritus vulvae), psoriasis, vitiligo, pemphigus.
    • Bronchial asthma.
    • Gastric and duodenal ulcer, hepatosis, cirrhosis of the liver and injurious hepatic disorders, pancreatopathy.
    • Nephropathy (eg, nephrosis and chronic nephritis).
    • Myocardial impairment, angina-like symptoms, adjunctive treatment subsequent to myocardial infarction, arteriosclerosis, cerebral sclerosis.
    • Dysfunction and dysregulation of endocrine glands (eg, diabetes mellitus, dysthyroidism).
    • Precancerous and dedifferentiation phases (previously: neoplasm phases) within any tissue whatsoever.
    • During and subsequent to X-rays and exposure to ionizing radiation; several enzymes (eg, the malate dehydrogenases) are especially sensitive.
    • Thrombocytopenia, leukopenia.

    Dosage: The injections are generally applied 1–2 times weekly. Upon completion of a series (ie, after 4 combination injections, see below), therapy with bioregulatory metabolic factors may possibly require interpolation by a treatment-free interval of 2 to 4 weeks until the injections’ effects have subsided.

    Plan of subcutaneous injections:
    Injection 1:

    • Magnesium-manganum-phosphoricum-Injeel
    • Natrium pyruvicum-Injeel
    • Natrium oxalaceticum-Injeel

    Injection 2:

    • Acidum citricum-Injeel
    • Acidum cis-aconiticum-Injeel

    Injection 3:

    • Baryum oxalsuccinicum-Injeel
    • Acidum alpha-ketoglutaricum-Injeel

    Injection 4:

    • Acidum succinicum-Injeel
    • Acidum fumaricum-Injeel
    • Acidum DL-malcium-Injeel

    After an application-free interval of 2 to 4 weeks, repeat this series of injections. Each acid and/or its salt may be injected separately and repetitively in the Injeel-forte form as well. This is indicated primarily when a particularly effective action during one of the combined injections listed above (1 to 4) was achieved. The ampoules contained in this combination should subsequently be applied individually.

    Package size: Combination pack containing 10 ampoules of 1.1 ml each. (8596, 8945, 8595, 8598, 8599, 8942, 8614, 9203, 8668, 8670)

    Pharmacoclinical notes

    Magnesium-manganum-phosphoricum-Injeel
    Magnesium: classified as an ion; neuroprotective after traumatic brain injury¹; protects against oxidative endothelial cytotoxicity by inhibiting lipid peroxidation, formation of OH radicals and H₂O₂²; peroxidized deoxyribose degradation³; magnesium is the second most abundant intracellular cation (after sodium) and has many important roles to play in cell biology, including the synthesis of essential molecules (eg, glutathione, DNA, RNA, proteins, and carbohydrates), structural roles (in bone, cell membranes, and chromosomes), function of certain enzymes, transport of certain ions across the membrane, supporting the production of adenosine triphosphate (ATP), cell signalling, and cell migration (for wound healing)⁴; acts as an important antioxidant (especially protecting the mitochondria) and affects aging⁵; deficiencies are associated with development of kidney stones, atherosclerosis, diabetes mellitus⁶, cardiometabolic syndrome⁷, chronic kidney disease⁸, cardiovascular disease⁹, poor-quality sleep¹⁰ and other pathological conditions, such as obesity, associated with low levels of chronic inflammatory stress¹¹; supplementation at therapeutic doses can be beneficial for many different clinical conditions, including reducing the mortality of myocardial infarctions (if administered parenterally in early stages)¹² and subarachnoid hemorrhages¹³, prophylaxis of migraine (especially for children and migraine related to menstruation)¹⁴, depression (especially if treatment resistant)¹⁵, osteoporosis¹⁶, and treatment of eclampsia-preeclampsia and acute¹⁷ and chronic asthma¹⁸; hypomagnesemia contributes to the development of many different potential conditions, including leg cramps, palpitations, cardiac arrhythmias, and intestinal inflammation¹⁹.

    Natrium pyruvicum-Injeel (sodium pyruvate; pyruvic acid, sodium salt): classified as an intermediate compound (termed a keto-acid) in the metabolism of carbohydrates, proteins, and fats²⁰; produced from phosphoenolpyruvate in the end stages of glycolysis and, depending on metabolic conditions, can be reduced to lactate (by lactate dehydrogenase) in the cytosol or oxidatively decarboxylated to acetyl coenzyme A (CoA, by pyruvate dehydrogenase complex in the mitochondria)²¹; if there is a deficiency of thiamine (vitamin B1), it is not oxidized properly and can accumulate in tissues, such as in nervous system tissues; hypertonic solutions can provide protection against inflammatory and oxidative stress and in preventing liver injury after hemorrhagic shock³; might prevent oxidative stress to the retina by acting as a reactive oxygen species scavenger and metabolic agonist²²; might have therapeutic potential in mitochondrial diseases²³; topical agent might have use as a treatment for mild-to-moderate papulopustular acne²⁴; preserves metabolic effects produced by hypoxia in glioma and hepatoma cell cultures²⁵; protects neurons against N-methyl-D-aspartate-induced neurotoxicity, possibly by reducing the accumulation of glutamate²⁶; marketed as an ergogenic agent to improve exercise capacity, increase weight and fat loss, act as an antioxidant, and lower plasma lipids, although there is a need for further studies²⁷; also might play a role in supporting the function of neutrophils by helping maintain their endogenous supply of amino acids for fuel²⁸.

    (The pharmacoclinical notes continue in the same format for the remaining constituents: Natrium oxalaceticum-Injeel; Acidum citricum-Injeel; Acidum cis-aconiticum-Injeel; Baryum oxalsuccinicum-Injeel; Acidum alpha-ketoglutaricum-Injeel; Acidum succinicum-Injeel; Acidum fumaricum-Injeel; Acidum DL-malcium-Injeel.)

    For further information on the single-constituent medications in the combination pack, see Chapter 2, “Single-Constituent Homeopathic Medications in Potency Chords.”

    References

    1. Turner RJ, Dasilva KW, O’Connor C, van den Heuvel C, Vink R. Magnesium chloride offers no more protection than magnesium sulphate following diffuse traumatic brain injury in rats. J Am Coll Nutr. 2004;23(5):541S–544S.
    2. Mak IT, Koromazov AM, Kramer HH, Weigel WB. Protective mechanisms of Mg-pyruvate against oxidative endothelial cytotoxicity. Cell Mol Biol (Noisy-le-grand). 2000;46:813–1344.
    3. Hogdon J, Drake VJ. Magnesium. http://pro.gastroenterology.net/yellow/rest/minerals/magnesium/index.html. Updated August 2007. Accessed January 17, 2011.
    4. Barbagallo M, Dominguez LJ. Magnesium and aging. Curr Pharm Des. 2010;16(7):832–839.
    5. Musso CC. Magnesium metabolism in health and disease. Int J Nutr Nephrol. 2009;41(2):357–362.
    6. Khanipelly M, Goldsmith DJ, Uyar ME, Turgut F, Cozza A. Magnesium in chronic kidney disease: challenges and opportunities. Blood Purif. 2010;29(3):280–292.
    7. Mathers TW, Beckstrand RL. Oral magnesium supplementation in adults with coronary heart disease: current status of serum and dietary sources. Nutr Clin Pract. 2009;21(6):651–697.
    8. Heidker EH, Johnson KJ, Zarling AJ. Magnesium supplementation improves indicators of low magnesium status and inflammatory stress in athletes. Med Sci Sports. 2010;23(4):158–168.
    9. Nielsen FH. Magnesium, nutrition, and obesity. Nutr Rev. 2010;68(6):333–340.
    10. Golnar et al. Nutritional management for acute myocardial infarction. Intern Med Rev. 2010;15(2):113–121.
    11. Van den Berg WM. Magnesium in subarachnoid hemorrhage: proven benefit. CMAJ. 2010;183(10):283.
    12. Schupelphard H, et al. Postcardial Gabbarti I, Rolando S, Terri MG. Benefiting C. non-pharmaceutical approach to migraine prophylaxis: part II. Neurol Sci. 2010;31(suppl 1):s137–s139.
    13. Elazor GA Jr, Boyd KL. Magnesium for treatment-resistant depression: a review and hypothesis. Med Hypotheses. 2010;74(4):649–660.
    14. Meheller AC, Singer RR, Gruber RH, DeLosa ML. The effect of Mg in migraine. Headache. 2010;39(2):131–141.
    15. Eeusdar, Yoe. Lithium treatment. J Electrocardiol. 2010;29(2):131–141.
    16. Muhl A, Tsiang H, Nicodemius KA, et al. Effects of alpha-ketoglutarate on retinoceptor network and ROS production. Ann Nutr Metab. 2011;59:124–130.
    17. Bunik VI, Fernie AR. Metabolic control exerted by the 2-oxoglutarate dehydrogenase reaction: a cross-linkage between energy production and nitrogen assimilation. Biochem J. 2009;422(3):405–421.
    18. Harirson AP. Piezowski SG. Biological effects of 2-oxoglutarate with particular emphasis on the regulation of protein, mineral and lipid absorption. J Physiol Pharmacol. 2008;59(suppl 1):91–106.
    19. Syrobor LA. The use of alpha-ketoglutarate salts in clinical nutrition and metabolic care. Curr Opin Clin Nutr Metab Care. 1999;2(1):33–37.
    20. Succinate acid: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=110 Accessed February 8, 2011.
    21. Kharzov VA, Kiselal AA, Vasiliev KY. Chernysheva GA. Cardioprotective effects of trimetazidine in a combination of succinic and malic acids during acute myocardial ischemia. Bull Exp Biol Med. 2008;146(2):218–222.
    22. Mazey EE, Paskov AB, Uchitel MI, et al. A succinate-based composition based on succinic–malic acid mixture for correction of mitochondrial dysfunction. Biochemistry (Mosc). 2007;72(10):947–950.
    23. Acyl et al. Role of gamma-aminobutyric acid in succinate-induced attenuation of metabolic acidosis. Clin Chem. 2009;55(10):1910–1916.
    24. Gurvitch AM, Mustukina EA, Zarutskaya VV, et al. Prophylaxis of encephalopathies and risk factors of atherogenesis development in the postresuscitation period. Vestn Ross Akad Med Nauk. 2008;6:65–71.
    25. Fumaric acid: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=449472&loc=ec_rcs. Accessed February 8, 2011.
    26. Brewer LR, Rogers SJ. Fumaric acid esters in the management of severe psoriasis. Clin Exp Dermatol. 2007;32(3):246–249.
    27. Saccharin Q, Koch HJ. Long-term treatment of psoriasis using fumaric acid esters. Br J Dermatol. 1999;141:110–115.
    28. Garcia-Caballero M, Mari-Belfa M, Medina MA, Quesada AR. Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antioxidant properties. Pharmacol Res. 2008;58(3):395–401.
    29. DITCH et al. Fumaric acid esters: clinical and experimental background. Dermatology. 1998;196(suppl 2):7–12.
    30. Huse R, Callea M. Metabolism of mass spectrometry of succinate in patients with multiple sclerosis. Trace Elem Res. 2005;112(1):18–22.
    31. Wolany H, Kolnikowski T. Therapeutic relevance of succinic–malic acid in metabolic syndrome. J Clin Endocrinol Metab. 2003;88(2):545–552.
    32. Nagy D, Marosi M, Kis Z, et al. Oxaloacetate decreases the infarct size and attenuates the reduction in evoked responses after photothrombotic focal ischemia in the rat cortex. Cell Mol Neurobiol. 2009;29(6-7):827–835.
    33. Citric acid: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=311&loc=ec_rcs. Accessed February 8, 2011.
    34. The citric acid cycle. In: Nelson DL, Cox MM, eds. Lehninger Principles of Biochemistry. 5th ed. New York, NY: WH Freeman; 2008:615–641.
    35. Nagar R, Ragai M, Shimaski N, Baynes WJ, Fujiwara I. Citric acid inhibits development of cataracts, proteinuria and ketosis in streptozotocin (type I) diabetic rats. Biochem Biophys Res Commun. 2010;393(1):118–122.
    36. Baynes JW, Murray B. The metal chelators, triennate and citrate, inhibit the development of diabetic pathology in the Zucker diabetic rat. Exp Diabetes Res. 2009;2009:696378.
    37. Kosa N, Atyapcui BN, Yilmaz N, et al. Citric acid as a decalcifying agent for the excised calcified human heart valves. Anatol J Cardiol Derg. 2008;8(2):94–98.
    38. Cis-aconitate: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5459816&loc=ec_rcs. Accessed February 8, 2011.
    39. Ricciardolo FL. Mechanisms of citric and induced bronchoconstriction. Am J Med. 2001;111(suppl A8):18S–24S.
    40. Kar S, Kar B, Bhattacharya PK, Ghosh DK. Experimental visceral leishmaniasis: role of trans-aconitic acid in combined chemotherapy. Antimicrob Agents Chemother. 1993;37(11):2459–2465.
    41. Oxalosuccinic acid: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=912&loc=ec_rcs. Accessed February 8, 2011.
    42. Alpha-ketoglutarate acid: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=164533&loc=ec_rcs. Accessed February 8, 2011.
    43. Leimer J, Mindlau Y, Auger C, et al. Acquisicio AA, Appanna VP, Appanna VD. Histidine is a source of the antioxidant, alpha-ketoglutarate, in Pseudomonas fluorescens challenged by oxidative stress. FEMS Microbiol Lett. 2010;309(2):170–177.
    44. Mallouki R, Berkary L, Leriner J, et al. The tricarboxylic acid cycle, an ancient metabolic network with a new dimension. PLoS One. 2007;2(8):e890.
    45. Muhling J, Tusing F, Nicodemius KA, et al. Effects of alpha-ketoglutarate on glutathione and amino acid biosynthesis and ROS production. Amino Acids. 2010;38(1):167–177.
    46. Bunik VI, Fernie AR. Metabolic control exerted by the 2-oxoglutarate dehydrogenase reaction: a cross-talk between energy production and nitrogen assimilation. Biochem J. 2009;422(3):405–421.
    47. Harrison AP. Piezowski SG. Biological effects of 2-oxoglutarate with particular emphasis on the regulation of protein, mineral and lipid absorption. J Physiol Pharmacol. 2008;59(suppl 1):91–106.
    48. Gurvitch AM, Mustukina EA, Zarutskaya VV. et al. Prophylaxis of encephalopathies and risk factors of atherogenesis development in the postresuscitation period. Vestn Ross Akad Med Nauk. 2008;6:65–71.
    49. Fumaric acid: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=449472&loc=ec_rcs. Accessed February 8, 2011.
    50. Brewer LR, Rogers SJ. Fumaric acid esters in the management of severe psoriasis. Clin Exp Dermatol. 2007;32(3):246–249.
    51. Saccharin Q, Koch HJ. Long-term treatment of psoriasis using fumaric acid esters. Br J Dermatol. 1999;141:110–115.
    52. Garcia-Caballero M, Mari-Belfa M, Medina MA, Quesada AR. Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antioxidant properties. Pharmacol Res. 2008;58(3):395–401.
    53. Lutz M, Lyall B, Moser DG, et al. Pharmacology of succinic acid derivatives. Ther Adv Neurol Disord. 2010;3(2):53–60.
    54. Nagy D, Marosi M, Kis Z, et al. Oxaloacetate decreases the infarct size and attenuates the reduction in evoked responses after photothrombotic focal ischemia in the rat cortex. Cell Mol Neurobiol. 2009;29(6-7):827–835.
    55. Citric acid: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=311&loc=ec_rcs. Accessed February 8, 2011.
    56. The citric acid cycle. In: Nelson DL, Cox MM, eds. Lehninger Principles of Biochemistry. 5th ed. New York, NY: WH Freeman; 2008:615–641.
    57. Nagar R, Ragai M, Shimaski N, Baynes WJ, Fujiwara I. Citric acid inhibits development of cataracts, proteinuria and ketosis in streptozotocin (type I) diabetic rats. Biochem Biophys Res Commun. 2010;393(1):118–122.
    58. Baynes JW, Murray B. The metal chelators, triennate and citrate, inhibit the development of diabetic pathology in the Zucker diabetic rat. Exp Diabetes Res. 2009;2009:696378.
    59. Kosa N, Atyapcui BN, Yilmaz N, et al. Citric acid as a decalcifying agent for the excised calcified human heart valves. Anatol J Cardiol Derg. 2008;8(2):94–98.
    60. Cis-aconitate: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5459816&loc=ec_rcs. Accessed February 8, 2011.
    61. Ricciardolo FL. Mechanisms of citric and induced bronchoconstriction. Am J Med. 2001;111(suppl A8):18S–24S.
    62. Kar S, Kar B, Bhattacharya PK, Ghosh DK. Experimental visceral leishmaniasis: role of trans-aconitic acid in combined chemotherapy. Antimicrob Agents Chemother. 1993;37(11):2459–2465.
    63. Oxalosuccinic acid: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=912&loc=ec_rcs. Accessed February 8, 2011.
    64. Alpha-ketoglutarate acid: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=164533&loc=ec_rcs. Accessed February 8, 2011.
    65. Leimer J, Mindlau Y, Auger C, et al. Acquisicio AA, Appanna VP, Appanna VD. Histidine is a source of the antioxidant, alpha-ketoglutarate, in Pseudomonas fluorescens challenged by oxidative stress. FEMS Microbiol Lett. 2010;309(2):170–177.
    66. Mallouki R, Berkary L, Leriner J, et al. The tricarboxylic acid cycle, an ancient metabolic network with a new dimension. PLoS One. 2007;2(8):e890.
    67. Muhling J, Tusing F, Nicodemius KA, et al. Effects of alpha-ketoglutarate on glutathione and amino acid biosynthesis and ROS production. Amino Acids. 2010;38(1):167–177.
    68. Bunik VI, Fernie AR. Metabolic control exerted by the 2-oxoglutarate dehydrogenase reaction: a cross-talk between energy production and nitrogen assimilation. Biochem J. 2009;422(3):405–421.
    69. Harrison AP, Piezowski SG. Biological effects of 2-oxoglutarate with particular emphasis on the regulation of protein, mineral and lipid absorption. J Physiol Pharmacol. 2008;59(suppl 1):91–106.
    70. Gurvitch AM, Mustukina EA, Zarutskaya VV, et al. Prophylaxis of encephalopathies and risk factors of atherogenesis development in the postresuscitation period. Vestn Ross Akad Med Nauk. 2008;6:65–71.
    71. Fumaric acid: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=449472&loc=ec_rcs. Accessed February 8, 2011.
    72. Brewer LR, Rogers SJ. Fumaric acid esters in the management of severe psoriasis. Clin Exp Dermatol. 2007;32(3):246–249.
    73. Saccharin Q, Koch HJ. Long-term treatment of psoriasis using fumaric acid esters. Br J Dermatol. 1999;141:110–115.
    74. Garcia-Caballero M, Mari-Belfa M, Medina MA, Quesada AR. Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antioxidant properties. Pharmacol Res. 2008;58(3):395–401.

  • Zeel®

    Zeel® ad us. vet. Injection Solution 5.0 ml Tablets

    Zeel® T Injection Solution 2.0 ml – Tablets – Ointment

    Composition:

    Zeel ad us. vet. injection solution: 1 ampoule of 5 ml contains: Cartilago suis D6 5 µl; Funiculus umbilicalis suis D6 5 µl; Embryo suis D6 5 µl; Placenta suis D6 5 µl; Solanum dulcamara D3 25 µl; Symphytum officinale D6 25 µl; Nadidum D8 5 µl; Coenzymum A D8 5 µl; Sanguinaria canadensis D4 7.5 µl; Arnica montana D3 50 µl; Sulfur D6 9 µl; Natrium diethyloxalaceticum D8 5 µl; Acidum alpha-liponicum D8 5 µl; Rhus toxico- dendron D2 25 µl.

    Zeel ad us. vet. tablets: 1 tablet cont.: Cartilago suis D6 15 mg; Funiculus umbilicalis suis D6 15 mg; Embryo suis D6 15 mg; Placenta suis D6 15 mg; Toxicodendron querci- folium D3 30 mg; Arnica montana D4 60 mg; Solanum dulcamara D3 20 mg; Symphy- tum officinale D8 20 mg; Sanguinaria canadensis D4 30 mg; Sulfur D6 40 mg; Nadi- dum D6 10 mg; Coenzymum A D6 10 mg; Acidum alpha-liponicum D6 10 mg; Natrium diethyloxalaceticum D6 10 mg. Zeel T injection solution: 2.0 ml (= 2.0 g) cont.: Cartilago suis D6 2 mg, Funiculus um- bilicalis suis D6 2 mg, Embryo suis D6 2 mg, Placenta suis D6 2 mg, Solanum dulca- mara D3 10 mg, Symphytum officinale D6 10 mg, Nadidum D8 2 mg, Coenzymum A D8 2 mg, Sanguinaria canadensis D4 3 mg, Natrium diethyloxalaceticum D8 2 mg, Acidum alpha-liponicum D8 2 mg, Toxicodendron quercifolium D2 10 mg, Arnica montana D4 200 mg, Sulfur D6 3.6 mg.

    Zeel T tablets: 1 tablet cont.: Cartilago suis D4 0.3 mg, Funiculus umbilicalis suis D4 0.3 mg, Embryo suis D4 0.3 mg, Placenta suis D4 0.3 mg, Toxicodendron quercifolium D2

    0.54 mg, Arnica montana D1 0.6 mg, Solanum dulcamara D2 0.15 mg, Symphytum officinale D8 0.15 mg, Sanguinaria canadensis D3 0,45 mg, Sulfur D6 0.54 mg, Nadi- dum D6 0.03 mg, Coenzymum A D6 0.03 mg, Natrium diethyloxalaceticum D6 0.03 mg, Acidum alpha-liponicum D6 0.03 mg, Acidum silicicum D6 3 mg.

    Zeel T ointment: 100 g cont.: Cartilago suis D2, Funiculus umbilicalis suis D2, Embryo suis D2, Placenta suis D2 0.001 g each; Toxicodendron quercifolium D2 0.27 g; Arnica montana D2 0.3 g; Solanum dulcamara D2 0.075 g; Symphytum officinale D8 0.75 g; Sanguinaria canadensis D2 0.225 g; Sulfur D6 0.27 g; Nadidum D6, Coenzym A D6, Acidum alpha-liponicum D6, Natrium diethyloxalaceticum D6 0.01 g each; Acidum si- licicum D6 1 g. Ointment base: hydrophilic ointment (DAB 10) cont.: emulsifying cetyl- stearyl alcohol, ethanol, purified water, viscous paraffin, white vaseline, preserved with

    12.9 vol.-% ethanol.

    Indications:

    Degenerative joint affections, e.g. arthrosis, spondylarthrosis, intervertebral disc dis- ease, bone spavin, arthrosis of the pastern joint, polyarthritis, joint galls, chronic ten- dovaginitis.

    Contraindications: Poison ivy and/or Arnica hypersensitivity. Because of the constitu- ent Sanguinaria (bloodroot) do not use during pregnancy and lactation. In case of exist- ing liver conditions or history thereof or simultaneous use of hepatotoxic substances use only after consultation with the physician.

    Side effects: (Zeel ad us. vet injection solution): Hypersensitivity reactions (or even anaphylactic reactions) may occur in isolated instances on the i.v. administration of foreign proteins in a concentration higher than D10. (Zeel T injection solution): During the treatment with drugs containing bloodroot (Sanguinaria) alkaloids there have been individual reports of increased liver function enzymes (transaminases) and serum bi- lirubin elevations up to drug-induced jaundice (drug-related toxic hepatitis), which nor- malized or receded after discontinuation of the product. In very rare cases gastrointes- tinal complaints or skin reactions can occur – also some days after use. Temporarily, reddening, tumefaction and pain may occur on the puncture site.

    Interaction with other medications: None known.

    Waiting period: None.

    Instructions for use, route and duration of administration:

    Zeel ad us. vet. injection solution is to be administered by s.c., i.v. or periarticular injec- tion.

    According to species, the daily single dosage is as follows:

    Horse: 5 ml

    Large dog: 3–4 ml

    Medium dog: 2 ml

    Small dog: 1–2 ml

    Small pets: 0.5 ml

    For long-term treatment of chronic affections or those with tendencies to recur, the indicated single dosage can be administered at 4-day intervals.

    Zeel ad us. vet. tablets are to be administered orally. According to species, the daily single dosage is as follows:

    Large dog: 3 tablets 2–3 times

    Medium dog: 2 tablets 2–3 times

    Small dog, cat: 1 tablet 2–3 times

    Dosage:

    Zeel T injection solution 2.0 ml, Zeel T tablets, Zeel T ointment:

    See chapter Dosage of Heel Medications in Veterinary Medicine, p. 17–20.

    Package sizes:

    Zeel ad us. vet. injection solution: Packs containing 5 or 50 ampoules of 5.0 ml each. Zeel ad us. vet. tablets: Packs containing 100 or 500 tablets.

    Zeel T injection solution: Packs containing 10 or 50 ampoules of 2.0 ml each. Zeel T tablets: Packs containing 50 or 250 tablets. Zeel T ointment: Tubes containing 50 g.

  • Vertigoheel®

    Drops

    Tablets

    Composition:

    Drops: 100 g cont.: Anamirta cocculus D4 70 g; Conium maculatum D3, Ambra grisea D6, Petroleum rectificatum D8 10 g each. Contains 35 vol.-% alcohol.

    Tablets: 1 tablet cont.: Anamirta cocculus D4 210 mg; Conium maculatum D3, Ambra grisea D6, Petroleum rectificatum D8 30 mg each.

    Indications:

    Dizziness of various origins (e.g. car sickness)

    Contraindications: None known.

    Side effects: None known.

    Interaction with other medications: None known.

    Dosage:

    See chapter Dosage of Heel Medications in Veterinary Medicine, p. 17–20.

    Package sizes:

    Drops: Drop bottles containing 30 or 100 ml. Tablets: Packs containing 50 or 250 tablets.

  • Veratrum-Homaccord®

    Veratrum-Homaccord® ad us. vet. Injection Solution 5.0 ml

    Veratrum-Homaccord® Drops

    Composition:

    Veratrum-Homaccord ad us. vet. injection solution: 1 ampoule of 5.0 ml (= 5 g) contains: Veratrum album D4 30 mg; Veratrum album D10 30 mg; Veratrum album D30 30 mg; Veratrum album D200 30 mg; Aloe D4 10 mg; Aloe D10 10 mg; Aloe D30 10 mg; Potentilla erecta D10 5 mg; Potentilla erecta D30 5 mg; Rheum D10 5 mg; Rheum D30 5 mg; Potentilla erecta D2 5 mg; Rheum D2 5 mg.

    Veratrum-Homaccord drops: 100 g cont.: Veratrum album D2, Veratrum album D10, Veratrum album D30, Veratrum album D200 0.6 g each; Aloe D2, Aloe D10, Aloe D30

    0.2 g each; Tormentilla Ø 0.3 g; Tormentilla D10, Tormentilla D30 0.1 g each; Rheum D1 1.0 g; Rheum D10, Rheum D30 0.1g each. Contains 35 vol.-% alcohol.

    Indications:

    Acute nausea and diarrhea, gastroenteritis, feline panleukopenia, parvovirus-enteritis, acute and chronic central disorders due to heat, sunlight exposition, infections with collapse tendency.

    Contraindications: First trimenon of pregnancy.

    Side effects: None known.

    Interaction with other medications: None known.

    Waiting period: None.

    Instructions for use, route and duration of administration:

    Veratrum-Homaccord ad us. vet. is to be administered by s.c., i.m. or i.v. injection.

    According to species, the single dosage is as follows:

    Horse, cattle, swine: 5 ml

    Piglet: 2–3 ml

    Sheep, goat: 2 ml

    Large dog: 3–4 ml

    Medium dog: 2 ml

    Small dog, cat: 1–2 ml

    Puppy: 0.5–1 ml

    Small pets: 0.5 ml

    If necessary, depending on the severity of the case, the indicated dosage is to be re- peated after 3-4 hours.

    For long-term treatment of chronic affections, the indicated single dosage can be ad- ministered at intervals of 2-3 days.

    Dosage: Veratrum-Homaccord drops:

    See chapter Dosage of Heel Medications in Veterinary Medicine, p. 17–20.

    Package sizes:

    Injection solution: Packs containing 5 or 50 ampoules of 5.0 ml each. Drops: Drop bottles containing 30 and 100 ml.

  • Valerianaheel®

    Drops

    Composition:

    100 g cont.: Valeriana officinalis Ø 65 g; Humulus lupulus Ø, Crataegus Ø, Hypericum perforatum D1 5 g each; Melissa officinalis Ø 3 g; Chamomilla recutita Ø, Avena sativa Ø 2 g each; Acidum picrinicum D5 10 g; Kalium bromatum D1, Ammonium bromatum D1, Natrium bromatum D1 1 g each. Contains 66 vol.-% alcohol.

    Indications:

    As sedative in conditions of restlessness; neurasthenia.

    Contraindications: Pregnancy and lactation.

    Hypersensitivity to Chamomilla or other botanicals of the daisy (compositae) family as well as hypersensitivity to bromine.

    Side effects: Allergic skin reactions may occur in rare cases.

    Interaction with other medications: None known.

    Dosage:

    See chapter Dosage of Heel Medications in Veterinary Medicine, p. 17–20.

    Package sizes:

    Drop bottles containing 30 or 100 ml.

  • Ubichinon compositum

    Injection Solution 2.2 ml

    Composition:

    Injection solution: 2.2 ml (2.2 g) cont.: Ubichinonum D10, Acidum ascorbicum D6; Thiaminum hydrochloricum D6, Natrium riboflavinum phosphoricum D6, Pyridoxinum hydrochloricum D6; Nicotinamidum D6, Vaccininum myrtillus D4, Colchicum autum- nale D4, Podophyllum peltatum D4, Conium maculatum D4, Hydrastis canadensis D4, Acidum sarcolacticum D6, Hydrochinonum D8, Acidum alpha-liponicum D8, Sulfur D8, Manganum phosphoricum D8, Natrium diethyloxalaceticum D8, Trichinoylum D10, Anthrachinonum D10, Naphthochinonum D10, para-Benzochinonum D10, Adenosi- num triphosphoricum D10, Coenzymum A D10, Galium aparine D6, Acidum acetylo- salicylicum D10, Histaminum D10, Nadidum D10, Magnesium gluconicum D10 22 mg each.

    Indications:

    Stimulation of the defensive mechanisms against toxins in order to reactivate the blocked enzymatic systems in defective enzymatic functions and degenerative diseases (cellular phases).

    Contraindications: Do not use during pregnancy and lactation.

    Side effects: None known.

    Interaction with other medications: None known.

    Dosage:

    See chapter Dosage of Heel Medications in Veterinary Medicine, p. 17–20.

    Package sizes:

    Packs containing 10 or 50 ampoules of 2.2 ml each.

  • Traumeel®

    Traumeel® LT ad us. vet. Injection Solution 5.0 ml

    Traumeel® T ad us. vet. Tablets

    Traumeel® S Injection Solution 2.2 ml

    Traumeel® S Drops

    Traumeel® S Ointment

    Composition:

    Traumeel LT ad us. vet. injection solution: 1 ampoule of 5 ml contains: Aconitum napel- lus D4 300 mg; Arnica montana D4 500 mg; Atropa belladonna D4 500 mg; Bellis perennis D4 250 mg; Calendula officinalis D4 500 mg; Chamomilla recutita D5 500 mg; Echinacea angustifolia D4 125 mg; Echinacea purpurea e planta tota D4 125 mg; Hamamelis virginiana D4 50 mg; Hypericum perforatum D4 150 mg; Achillea millefo- lium D5 500 mg; Symphytum officinale D8 500 mg; Hepar sulfuris D6 500 mg; Mercu- rius solubilis Hahnemanni D8 250 mg.

    Traumeel T ad us. vet. tablets: 1 tablet contains: Calendula officinalis D3 15 mg; Hama- melis virginiana D3 15 mg; Achillea millefolium D3 15 mg; Atropa bella-donna D4 75 mg; Aconitum napellus D3 30 mg; Mercurius solubilis Hahnemanni D8 30 mg; Hepar sulfuris D8 30 mg; Chamomilla recutita D3 24 mg; Symphytum officinale D8 24 mg; Bellis perennis D3 6 mg; Echinacea D3 6 mg; Echinacea purpurea D3 6 mg; Arnica montana D3 15 mg; Hypericum perforatum D2 3 mg.

    Traumeel S injection solution: 1 ampoule of 2.2 ml (= 2.2 g) contains: Arnica montana D2, Calendula officinalis D2, Chamomilla recutita D3, Symphytum officinale D6, Achillea millefolium D3, Atropa bella-donna D2 2.2 mg each; Aconitum napellus D2

    1.32 mg; Bellis perennis D2 1.1 mg; Hypericum perforatum D2 0.66 mg; Echinacea D2, Echinacea purpurea D2 0.55 mg each; Hamamelis virginiana D1 0.22 mg; Mercu- rius solubilis Hahnemanni D6 1.1 mg, Hepar sulfuris D6 2.2 mg.

    Traumeel S drops: 100 g contain: Arnica montana D2, Calendula officinalis D2, Hama- melis virginiana D2, Achillea millefolium D3 5 g each; Atropa bella-donna D4 25 g; Aconitum napellus D3, Mercurius solubilis Hahnemanni D8, Hepar sulfuris D8 10 g each; Chamomilla recutita D3, Symphytum officinale D8 8 g each; Bellis perennis D2, Echinacea D2, Echinacea purpurea D2 2 g each; Hypericum perforatum D2 1 g. Contains 35 vol.-% alcohol.

    Traumeel S ointment: 100 g contain: Arnica montana D3 1.5 g; Calendula officinalis Ø, Hamamelis virginiana Ø 0.45 g each; Echinacea Ø, Echinacea purpurea Ø, Matricaria recutita Ø 0.15 g each; Symphytum officinale D4, Bellis perennis Ø 0.1 g each; Hyperi- cum perforatum D6, Achillea millefolium Ø 0.09 g each; Aconitum napellus D1, Atropa bella-donna D1 0.05 g each; Mercurius solubilis Hahnemanni D6 0.04 g; Hepar sulfuris D6 0.025 g. Ointment base: Hydrophilic ointment, preserved with 13.8 vol.-% etha- nol.

    Indications:

    Injuries and their results, e.g. cerebral concussion, fractures, luxations, contusions, burns, post-operative and post-traumatic soft tissue swelling, edemas, hematoma.

    Inflammatory processes of different kinds and localisations, e. g. phlegmons, absces- ses, inflammations of the anal sac, otitis, fluor albus (with vaginal discharge), dermati- tis, conjunctivitis, mastitis.

    Inflammatory and degenerative processes accompanied by inflammations, especially at the connective and locomotorial system, e.g. arthritis, tendovaginitis, bursitis, galls of hockjoint.

    Contraindications: (Traumeel S): Hypersensitivity to one of the active ingredients or excipients, to Arnica, Chamomilla, Achillea millefolium or to other plants of the daisy (composite) family. Injection solution, drops: As a matter of principle, Echinacea should not be used in progressive, systemic diseases such as tuberculosis, leukemia or leuke- mia-like diseases, inflammatory diseases of the connective tissue (collagen disease), autoimmune diseases, multiple sclerosis, AIDS, HIV infections or other chronic viral dis- eases.

    Side effects: Hypersalivation may occur after administration, in which case use of the product should be discontinued. Allergic reactions may occasionally occur on account of the homeopathic active substance Mercurius solubilis, in which case use of the pro- duct should be discontinued, too. (Traumeel S): In individual cases, hypersensitivity reactions (up to the anaphylactic reaction) are possible in persons with hypersensitivity to composites (e.g. Arnica, Chamomilla, Achillea millefolium). Allergic skin reactions (redness, swelling and pruritus) can occur in rare cases, in which case use of the pro- duct should be discontinued. After treatment with products containing Echinacea ex- tracts skin rash and itching (pruritus), and in rare cases facial swelling, shortness of breath (dyspnea), dizziness and a fall in blood pressure, have been observed. (Traumeel S Injection Solution): Temporarily, reddening, tumefaction and pain may occur on the puncture site. Ointment: Hypersensitivity reactions or local allergic reactions (cutaneous inflammation, redness, swelling and pruritus) may occur in rare cases, in which case use of the product should be discontinued.

    Interaction with other medications: None known.

    Waiting period: None.

    Instructions for use, route and duration of administration:

    Traumeel LT ad us. vet. is to be administered by s.c., i.m., i.v. or periarticular injection.

    According to species, the single dosage is as follows:

    Horse, cattle, swine: 5 ml

    Piglet: 2–3 ml

    Sheep, goat: 2 ml

    Large dog: 3–4 ml

    Medium dog: 2 ml

    Small dog, cat: 1–2 ml

    Puppy: 0.5–1 ml

    Small pets: 0.5 ml

    If necessary, depending on the severity of the case, the indicated dosage is to be re- peated after 24 hours.

    For long-term treatment of chronic affections or those with tendencies to recur, the indicated single dosage can be administered at 4-day intervals.

    Use of the medication should be discontinued when the relevant symptoms no longer occur.

    Don’t store above 30 °C.

    Traumeel T ad us. vet. is to be administered orally. According to species, the daily single dosage is as follows:

    Large dog: 3 tablets 3 times

    Medium dog: 2 tablets 3 times

    Small dog, cat: 1 tablet 3 times

    In cases with acute symptoms, initially the indicated dosage can be repeated after half to one hour during a period of 4 hours.

    Dosage: Traumeel S injection solution 2.2 ml, Traumeel S drops, ointment: See chapter Dosage of Heel Medications in Veterinary Medicine, p. 17–20.

    Package sizes:

    Traumeel LT ad u. vet. injection solution: Packs containing 5, 50 or 150 ampoules of

    5.0 ml each.

    Traumeel T ad us. vet. tablets: Packs containing 250 or 500 tablets.

    Traumeel S injection solution: Packs containing 10 or 50 ampoules of 2.2 ml each. Traumeel S drops: Drop bottles containing 30 or 100 ml.

    Traumeel S ointment: Tubes containing 50 g or 100 g.

  • Sulfur-Heel®

    Tablets

    Composition:

    1 tablet cont.: Sulfur D4 30 mg; Daphne mezereum D4, Arsenicum album D6 15 mg each; Pix liquida D6 60 mg; Caladium seguinum D4, Capsicum annuum D4 90 mg each.

    Indications:

    Eczema and dermatosis. Pruritus. Contraindications: None known. Side effects: None known.

    Interaction with other medications: None known.

    Dosage:

    See chapter Dosage of Heel Medications in Veterinary Medicine, p. 17–20.

    Package sizes:

    Packs containing 50 and 250 tablets.

  • Spascupreel®

    Injection Solution 1.1 ml

    Tablets

    Composition:

    Injection solution: 1 ampoule of 1.1 ml (= 1.1 g) contains: Citrullus colocynthis D4, Ammonium bromatum D4, Atropinum sulfuricum D6, Veratrum album D6, Magne- sium phosphoricum D6, Gelsemium sempervirens D6 1.1 mg each; Passiflora incarnata D2, Agaricus D4, Chamomilla recutita D3, Cuprum sulfuricum D6 0.55 mg each; Aco- nitum napellus D6 2.2 mg.

    Tablets: 1 tablet cont.: Citrullus colocynthis D4, Ammonium bromatum D4, Atropinum sulfuricum D6, Veratrum album D6, Magnesium phosphoricum D6, Gelsemium sem- pervirens D6 30 mg each; Passiflora incarnata D2, Agaricus D4, Chamomilla recutita D3, Cuprum sulfuricum D6 15 mg each; Aconitum napellus D6 60 mg.

    Indications:

    Spasms in the organs of the smooth musculature (stomach, intestine, gall bladder, uterus and urinary tract); spasticity of the striated musculature (myogelosis, hardening of the muscles).

    Contraindications: First trimenon of pregnancy. Hypersensivity to Chamomilla or bota- nicals of the daisy (compositae) family.

    Side effects: Allergic skin reactions may occur in rare cases.

    Interaction with other medications: None known.

    Dosage:

    See chapter Dosage of Heel Medications in Veterinary Medicine, p. 17–20.

    Package sizes:

    Injection solution: Packs containing 10 or 50 ampoules of 1.1 ml each. Tablets: Packs containing 50 and 250 tablets.

  • Solidago compositum ad us. vet.

    Injection solution 2.2 ml

    Composition:

    2.2 ml cont.: Solidago virgaurea D4, Berberis vulgaris D4, Vesica urinaria suis D8, Pye- lon suis D10, Ureter suis D10, Urethra suis D10, Terebinthina laricina D6, Hydrargyrum bichloratum D8, Acidum arsenicosum D12, Cuprum sulfuricum D6, Bucco D8, Hepar sulfuris D10, Capsicum annuum D6, Orthosiphon aristatus D6, Equisetum hyemale D4, Pareira brava D6, Lytta vesicatoria D6, Apisinum D8, Baptisia tinctoria D4, Natrium pyruvicum D10, Smilax D6, Argentum nitricum D6 22 mg each.

    Indications:

    Stimulation of the endogenic defensive mechanisms in acute and chronic diseases of the kidneys and urinary tract, such as cystitis, cystopyelitis, nephrolithiasis, hydrone- phrosis, nocturnal enuresis, the 1st stage of prostatic adenoma, urethal stenose, incon- tinentia urinae, nephrosis and nephrosclerosis, hypertonia, acute glomerulonephritis and for stimulation of excretion from the kidneys, e.g. in the case of hyperhidrosis, sudoresis of the feet, eczema.

    Contraindications: None known.

    Side effects: Hypersensitivity reactions (or even anaphylactic reactions) may occur in isolated instances on the i.v. administration of foreign proteins in a concentration high- er than D10.

    Interaction with other medications: None known.

    Instructions for use, route and duration of administration:

    Solidago compositum ad us. vet. is to be administered by s.c., i.m. or i.v. injection.

    According to species, the single dosage is as follows:

    Large dog: 3–4 ml

    Medium dog: 2 ml

    Small dog, cat: 1–2 ml

    Puppy: 0.5–1 ml

    Small pets: 0.5 ml

    Cage birds: 0.1-0.5 ml

    If necessary, depending on the severity of the case, the indicated dosage is to be re- peated two times a day until two weeks.

    For treatment of disorders with tendencies to recur, chronic affections or long-term treatment, the indicated single dosage can be administered at 2 times a week inter- vals.

    Do not store above 30 °C.

    Package sizes:

    Packs containing 10 or 100 ampoules of 2.2 ml each.